BRCA1 and cancer: All patients have previously been tested and found to be negative for any deleterious change in CDKN2A. Targeted sequencing of BRCA1/2 in the 96 MM patients and an additional 30 melanoma cases with a familial aggregation of cancers that included breast cancer.